Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
2.63
USD
|
-2.95%
|
|
-11.74%
|
+192.22%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
434.5
|
431.1
|
477.5
|
177.3
|
73.18
|
35.1
|
Enterprise Value (EV)
1 |
430.6
|
399.2
|
372.3
|
108.5
|
40.88
|
31.09
|
P/E ratio
|
-7.75
x
|
-10
x
|
-6
x
|
-2.75
x
|
-2.21
x
|
-1.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
2,652,917,178
x
|
131,246,785
x
|
54,170,110
x
|
20,045,481
x
|
EV / Revenue
|
-
|
-
|
2,068,339,400
x
|
80,326,725
x
|
30,256,712
x
|
17,757,074
x
|
EV / EBITDA
|
-7.49
x
|
-9.92
x
|
-5.81
x
|
-1.64
x
|
-1.1
x
|
-1.36
x
|
EV / FCF
|
-23.8
x
|
-12.1
x
|
-13.6
x
|
-2.72
x
|
-1.54
x
|
-1.43
x
|
FCF Yield
|
-4.2%
|
-8.28%
|
-7.36%
|
-36.8%
|
-65%
|
-69.8%
|
Price to Book
|
-56
x
|
14.3
x
|
5.41
x
|
6.61
x
|
-12.3
x
|
-1.31
x
|
Nbr of stocks (in thousands)
|
23,175
|
27,816
|
39,141
|
39,142
|
38,928
|
39,000
|
Reference price
2 |
18.75
|
15.50
|
12.20
|
4.530
|
1.880
|
0.9000
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.18
|
1.351
|
1.351
|
1.751
|
EBITDA
1 |
-57.5
|
-40.23
|
-64.13
|
-66.18
|
-37.01
|
-22.81
|
EBIT
1 |
-57.54
|
-40.31
|
-64.21
|
-66.24
|
-37.24
|
-23.11
|
Operating Margin
|
-
|
-
|
-35,672.78%
|
-4,903.03%
|
-2,756.4%
|
-1,320.05%
|
Earnings before Tax (EBT)
1 |
-57.47
|
-40.33
|
-63.82
|
-64.64
|
-36.12
|
-21.84
|
Net income
1 |
-54.87
|
-38.08
|
-60.97
|
-64.18
|
-33.28
|
-21.03
|
Net margin
|
-
|
-
|
-33,873.89%
|
-4,750.48%
|
-2,463.29%
|
-1,200.8%
|
EPS
2 |
-2.421
|
-1.545
|
-2.033
|
-1.645
|
-0.8513
|
-0.5392
|
Free Cash Flow
1 |
-18.1
|
-33.05
|
-27.41
|
-39.91
|
-26.58
|
-21.7
|
FCF margin
|
-
|
-
|
-15,226.67%
|
-2,953.99%
|
-1,967.65%
|
-1,239.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
4/29/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 S1
|
---|
Net sales
1 |
0.337
|
0.338
|
-
|
EBITDA
1 |
-18.33
|
-10.48
|
-
|
EBIT
1 |
-18.35
|
-10.49
|
-
|
Operating Margin
|
-5,444.81%
|
-3,104.14%
|
-
|
Earnings before Tax (EBT)
1 |
-17.56
|
-9.746
|
-
|
Net income
1 |
-18.37
|
-9.513
|
-18.49
|
Net margin
|
-5,451.04%
|
-2,814.5%
|
-
|
EPS
2 |
-0.4700
|
-0.2400
|
-0.4700
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
12/30/21
|
4/14/22
|
2/28/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3.89
|
32
|
105
|
68.8
|
32.3
|
4.01
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-18.1
|
-33.1
|
-27.4
|
-39.9
|
-26.6
|
-21.7
|
ROE (net income / shareholders' equity)
|
-616%
|
-371%
|
-104%
|
-115%
|
-310%
|
166%
|
ROA (Net income/ Total Assets)
|
-180%
|
-97.6%
|
-49.7%
|
-41.7%
|
-36.4%
|
-40.7%
|
Assets
1 |
30.43
|
39.02
|
122.8
|
154
|
91.42
|
51.69
|
Book Value Per Share
2 |
-0.3300
|
1.090
|
2.260
|
0.6900
|
-0.1500
|
-0.6900
|
Cash Flow per Share
2 |
0.1700
|
1.290
|
2.800
|
1.070
|
0.8800
|
0.2000
|
Capex
1 |
0.21
|
0
|
0.05
|
2.84
|
0.03
|
0.1
|
Capex / Sales
|
-
|
-
|
28.89%
|
210.51%
|
2.52%
|
5.71%
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
4/29/24
|
|
1st Jan change
|
Capi.
|
---|
| +192.22% | 103M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|